221 Participants Needed

ProVee Urethral Expander System for Benign Prostatic Hyperplasia

(ProVIDE Trial)

Recruiting at 16 trial locations
ML
DG
NW
Overseen ByNing Wu
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing a new device called the ProVee Urethral Expander System. It aims to help men who have trouble urinating because of an enlarged prostate. The device works by widening the urethra, making it easier for urine to pass through.

Will I have to stop taking my current medications?

Yes, you may need to stop taking certain medications before joining the trial. The trial requires stopping some medications like alpha-blockers, 5-alpha-reductase inhibitors, and certain others within specific timeframes before the study begins.

Is the ProVee Urethral Expander System safe for humans?

The ProVee Urethral Expander System, also known as the Urocross Expander System, was evaluated in a pre-clinical study using a canine model to assess its safety and tissue response. While this study provides some safety insights, it is important to note that it was not conducted in humans.12345

How is the ProVee Urethral Expander System treatment different from other treatments for benign prostatic hyperplasia?

The ProVee Urethral Expander System is unique because it is designed to physically expand and reshape the prostatic urethra, which is different from other treatments that may involve medication or surgical procedures. This approach aims to relieve urinary symptoms by directly addressing the physical constriction caused by an enlarged prostate.14678

What data supports the effectiveness of the ProVee Urethral Expander System treatment for benign prostatic hyperplasia?

The ProVee Urethral Expander System is similar to the Prostatic Urethral Lift (PUL), which has shown positive results in treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) in several studies. These studies reported improvements in symptoms and quality of life over three to five years, suggesting that similar treatments can be effective for BPH.79101112

Are You a Good Fit for This Trial?

Men with symptoms of urinary obstruction due to benign prostatic hyperplasia (BPH), who haven't had prostate/bladder cancer, urinary stones, blood in urine recently, or prior prostate procedures. Candidates should not be on medications like finasteride or dutasteride for urination issues and have a prostate size between 30 cc and 80 cc.

Inclusion Criteria

I have been diagnosed with an enlarged prostate.
I have not had any procedures done on my prostate.
I have tried and cannot tolerate medication for urinary symptoms, or I choose not to take them.
See 4 more

Exclusion Criteria

I have taken medication to help with urination, like Proscar, Avodart, or Jalyn.
The length of a specific part of your prostate called the prostatic urethra is longer than 3.75cm, as measured by a special ultrasound exam called TRUS.
I have had procedures done on my prostate.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the ProVee Urethral Expander System or undergo a sham procedure

Procedure
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 months
Multiple visits (in-person)

Crossover

Subjects in the Sham Arm are given the opportunity to crossover to the ProVee Urethral Expander System after the 3-month follow-up

Post 3-month follow-up

What Are the Treatments Tested in This Trial?

Interventions

  • ProVee Urethral Expander System
Trial Overview The trial is testing the ProVee Urethral Expander System's safety and effectiveness compared to a standard urethral access sheath in men with BPH-related urinary problems. The goal is to see if this new device can improve symptoms by expanding the urethra.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Crossover ProVee Urethral Expander SystemExperimental Treatment1 Intervention
All subjects shall be unblinded following the 3 month follow-up visit. Those subjects randomized to the Sham Arm will be given the opportunity to "crossover" to the ProVee Urethral Expander System.
Group II: Device: The ProVee Urethral Expander SystemActive Control1 Intervention
The ProVee Urethral Expander System consists of two components: a nitinol Expander implant and a 19Fr Delivery System designed to allow the Expander to be deployed under direct vision for the treatment arm.
Group III: Sham: Ureteroscope and urethral access sheathPlacebo Group1 Intervention
An ureteroscope housed within the inner lumen of an urethral access sheath will be used under direct vision for the Sham procedure.

Find a Clinic Near You

Who Is Running the Clinical Trial?

ProVerum Medical

Lead Sponsor

Trials
3
Recruited
280+

Published Research Related to This Trial

The Urocross Expander System was successfully implanted in 8 male canines, leading to a significant increase in urethral width (from 6.9 mm to 10.2 mm) without causing obstruction or retention, indicating its potential efficacy for treating urinary tract symptoms.
The device showed a favorable safety profile, with minimal adverse events and no significant tissue growth, encrustation, or stone formation observed post-retrieval, suggesting it may be a safe option for managing benign prostatic hyperplasia.
Characterization of a Novel Implant Intended to Expand and Reshape the Prostatic Urethra for the Treatment of Benign Prostatic Hyperplasia: A Pre-Clinical Feasibility Study in the Canine Model.Chughtai, B., Punyala, A., Lata, SS., et al.[2022]
A review of 2567 reports on various BPH treatment devices showed that over 99% of patients experienced no complications from device malfunctions, indicating a high level of safety across the modalities studied.
The use of morcellators during HoLEP was associated with the highest rate of serious complications, suggesting that urologists should be cautious and choose devices they are most familiar with to minimize risks.
Device Malfunctions and Complications Associated with Benign Prostatic Hyperplasia Surgery: Review of the Manufacturer and User Facility Device Experience Database.Patel, NH., Uppaluri, N., Iorga, M., et al.[2021]
In a study of 3,047 men with lower urinary tract symptoms due to benign prostatic hyperplasia, the first year of treatment with doxazosin, finasteride, or combination therapy showed significantly higher rates of adverse experiences, particularly sexual function issues and dizziness.
Men on combination therapy reported the highest incidence of adverse effects in the first year, with rates 3.4 to 10.6 times higher than after the first year, highlighting the importance of monitoring and discussing these potential side effects with patients during initial treatment.
Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial.Kaplan, SA., Lee, JY., Meehan, AG., et al.[2022]

Citations

Three year results of the prostatic urethral L.I.F.T. study. [2022]
The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. [2022]
Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. [2022]
Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment. [2019]
Updated results of a randomized, double-blind, multicenter sham-controlled trial of microwave thermotherapy with the Dornier Urowave in patients with symptomatic benign prostatic hyperplasia. Urowave Investigators Group. [2019]
Characterization of a Novel Implant Intended to Expand and Reshape the Prostatic Urethra for the Treatment of Benign Prostatic Hyperplasia: A Pre-Clinical Feasibility Study in the Canine Model. [2022]
Device Malfunctions and Complications Associated with Benign Prostatic Hyperplasia Surgery: Review of the Manufacturer and User Facility Device Experience Database. [2021]
Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial. [2022]
Durable benefit after treatment of obstructive benign prostatic hyperplasia with a novel drug-device combination product: 2-year outcomes from the EVEREST-I study. [2023]
Long-term clinical results and quality of life after insertion of a self-expanding flexible endourethral prosthesis. [2019]
11.United Statespubmed.ncbi.nlm.nih.gov
Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. [2022]
How I Do It: Optilume BPH catheter system. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security